These findings suggested that therapeutic NLRP3 inhibition could alleviate pathological α-syn and p-Tau accumulations in METH-treated mice, consistent with findings of a recent study that showed that pharmacological inhibition of NLRP3 could protect against α-syn pathology in a Parkinson’s disease mice model (Gordon et al., 2018). The gene discussed is MAPT; the disease is Parkinson disease.